Rosa’s PhysioPD™ Research fundamentally improves decision making at critical steps in drug development.
These case studies show the value of PhysioPD Research, and our ability to reduce and front-load risk, which has had a transformative impact on the economics of drug development for our clients.”— Ron Beaver, Founder, Chairman and CEO of Rosa & Co.
SAN CARLOS, CA, USA, October 15, 2019 -- Results from seven studies presented at the Tenth American Conference on Pharmacometrics (ACoP10) demonstrate the value of Rosa & Co.’s brand of quantitative systems pharmacology (QSP) – PhysioPD Research – in increasing confidence and reducing risk in drug development. These studies demonstrate improved candidate selection, clarification of disease and drug mechanisms, and the use of PhysioPD Research to extrapolate clinical results from adults to children to reduce risk in pediatric drug development. More...https://www.einpresswire.com/a...